<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178396</url>
  </required_header>
  <id_info>
    <org_study_id>15F.572</org_study_id>
    <secondary_id>R01HL096593</secondary_id>
    <nct_id>NCT03178396</nct_id>
  </id_info>
  <brief_title>Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets</brief_title>
  <official_title>Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be studying the effect of melatonin on blood pressure, insulin
      resistance, and platelets, along with possible reasons for how melatonin cases these effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will be studying the effect of melatonin on blood pressure and insulin
      resistance, and possible reasons for how melatonin works on blood pressure and IR. Along with
      blood testing to measure adipokines, insulin resistance (IR), and platelet function (how well
      your blood clots), 24-hour ambulatory blood pressure monitoring (ABPM) will be used to
      measure blood pressure, since ABPM is the gold standard (best method) for accurate assessment
      of blood pressure status and associated cardiovascular risk. Vascular (blood vessel)
      function, IR, adipokine levels and sleep quality will also be measured. All study endpoints
      will be measured at baseline and following 6 weeks of daily melatonin 9 mg dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2015</start_date>
  <completion_date type="Actual">August 9, 2016</completion_date>
  <primary_completion_date type="Actual">August 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Office Systolic Blood pressure change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in Systolic blood pressure measured in the office at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Office Diastolic Blood pressure change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in Diastolic blood pressure measured in the office at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory Systolic Blood pressure change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in 24 hour average Systolic blood pressure at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory Diastolic Blood pressure change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in 24 hour average Diastolic blood pressure at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA: Homeostasis Model Assessment change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Insulin sensitivity measure change at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QUICKI: Quantitative insulin sensitivity check index change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Insulin sensitivity measure change at 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arachidonic acid stimulated aggregation change</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Platelet activity measure change at 6 weeks</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Prehypertension</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Young, intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients ages 18-45, taking melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young, control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients ages 18-45, usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older, intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients ages 60 and older, taking melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older, control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients ages 60 and older, usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks</description>
    <arm_group_label>Young, intervention</arm_group_label>
    <arm_group_label>Older, intervention</arm_group_label>
    <other_name>Life Extension Foundation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normotensive (SBP &lt;120) or prehypertensive (SBP = 120-139 mm Hg)

          -  Age: Young/middle-aged (ages 18-45) and (2) 10 elderly subjects ages 65 and older

        Exclusion Criteria:

          -  Patients with a diagnosis of

               -  clinical hypertension and/or diabetes mellitus

               -  pregnancy

               -  coronary or cerebrovascular disease

               -  collagen vascular disease,

               -  organ failure (heart, kidney, liver).

          -  Patients taking anti-inflammatory medications: NSAIDs, corticosteroids,
             thiazolidinediones, and statins,

          -  Patients who have taken melatonin previously in the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Cheng, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Summarized data, available immediately by contacting PI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

